DYN
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases. The company's therapies deliver nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision, enabling patients to restore muscle strength and transform their lives.
Dyne Therapeutics, Inc. (DYN) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (F). The rating has held at D+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | C- (2.0) | C- (2.0) | C- (2.0) | F (0.0) | D+ (1.7) |
| 2026-11-04 | C+ (2.5) | C- (1.9) | C- (2.0) | C- (1.9) | F (0.0) | D+ (1.7) |
| 2026-10-28 | C+ (2.5) | C- (1.9) | C- (2.0) | C- (1.9) | F (0.0) | D+ (1.7) |
| 2026-10-21 | C+ (2.5) | D+ (1.8) | C- (2.0) | C- (2.0) | F (0.0) | D+ (1.7) |
| 2026-10-14 | C+ (2.5) | C- (1.9) | C- (2.0) | C- (2.1) | F (0.0) | D+ (1.7) |